Fund holdings
Baker Bros. Advisors — SEC 13F
as of Jun 30, 2026 · Older snapshot
Filed · Aug 14, 2026
These are the investment manager’s reported positions, not the named person’s personal brokerage holdings. Form 13F shows reportable long securities at quarter-end and omits cash, short positions and many foreign/private assets. Showing 83 of 83 reported share positions; full filings are linked. 1 option, principal-amount or warrant/debt rows are excluded. Option figures describe underlying exposure, not option premiums. Allocation is within the reported non-option share positions, not total fund assets. 13F does not disclose purchase costs or actual P&L.
| Security | Allocation | Shares | Cost basis | Market value | Unrealized P&L |
|---|---|---|---|---|---|
| CUSIP 45337C102Incyte Corporation — COM | 17.54% | 30,762,330 | Not disclosed | $3,487,217,729.00Jun 30, 2026 | Not disclosed |
| CUSIP 07725L102BeOne Medicines Ltd. — SPONSORED ADS | 12.61% | 8,801,567 | Not disclosed | $2,508,182,548.00Jun 30, 2026 | Not disclosed |
| CUSIP 76155X100Revolution Medicines, Inc. — COM | 10.78% | 11,443,357 | Not disclosed | $2,143,111,899.00Jun 30, 2026 | Not disclosed |
| CUSIP 558868105Madrigal Pharmaceuticals, Inc. — COM | 5.79% | 2,143,131 | Not disclosed | $1,150,754,190.00Jun 30, 2026 | Not disclosed |
| CUSIP 004225108ACADIA Pharmaceuticals Inc. — COM | 5.46% | 42,912,904 | Not disclosed | $1,085,696,471.00Jun 30, 2026 | Not disclosed |
| CUSIP 501575104Kymera Therapeutics, Inc. — COM | 4.99% | 8,657,242 | Not disclosed | $992,725,940.00Jun 30, 2026 | Not disclosed |
| CUSIP 457669307Insmed Incorporated — COM PAR $.01 | 4.72% | 8,796,111 | Not disclosed | $937,841,355.00Jun 30, 2026 | Not disclosed |
| CUSIP 15102K100Celcuity Inc. — COM | 4.16% | 7,915,792 | Not disclosed | $828,150,159.00Jun 30, 2026 | Not disclosed |
| CUSIP 50015M109Kodiak Sciences Inc. — COM | 3.9% | 19,919,186 | Not disclosed | $776,051,487.00Jun 30, 2026 | Not disclosed |
| CUSIP 76243J105Rhythm Pharmaceuticals, Inc. — COM | 3.13% | 5,604,483 | Not disclosed | $622,265,747.00Jun 30, 2026 | Not disclosed |
| CUSIP 74006W207Praxis Precision Medicines, Inc. — COM | 2.95% | 1,753,198 | Not disclosed | $586,953,158.00Jun 30, 2026 | Not disclosed |
| CUSIP G01767105Alkermes plc — SHS | 2.64% | 10,012,267 | Not disclosed | $524,592,729.00Jun 30, 2026 | Not disclosed |
| CUSIP 86627T108Summit Therapeutics Inc. — COM | 2.4% | 32,786,348 | Not disclosed | $477,697,090.00Jun 30, 2026 | Not disclosed |
| CUSIP 384747101GRAIL, Inc. — COM | 1.38% | 4,028,614 | Not disclosed | $275,033,478.00Jun 30, 2026 | Not disclosed |
| CUSIP 00288U106AbCellera Biologics Inc. — COM | 1.3% | 33,012,138 | Not disclosed | $259,145,283.00Jun 30, 2026 | Not disclosed |
| CUSIP 45258J102Immunovant, Inc. — COM | 1.05% | 5,435,220 | Not disclosed | $209,419,027.00Jun 30, 2026 | Not disclosed |
| CUSIP 45166A102IDEAYA Biosciences, Inc. — COM | 0.94% | 5,010,030 | Not disclosed | $186,723,818.00Jun 30, 2026 | Not disclosed |
| CUSIP G52694109Kiniksa Pharmaceuticals International, plc — ORD SHS CL A | 0.91% | 2,834,643 | Not disclosed | $181,275,420.00Jun 30, 2026 | Not disclosed |
| CUSIP G76279101Roivant Sciences Ltd. — SHS | 0.84% | 4,716,831 | Not disclosed | $166,928,649.00Jun 30, 2026 | Not disclosed |
| CUSIP 04280A100Arrowhead Pharmaceuticals, Inc. — COM | 0.82% | 1,992,783 | Not disclosed | $162,431,742.00Jun 30, 2026 | Not disclosed |
| CUSIP 462222100Ionis Pharmaceuticals, Inc. — COM | 0.82% | 2,047,727 | Not disclosed | $162,364,274.00Jun 30, 2026 | Not disclosed |
| CUSIP 28036F105Edgewise Therapeutics, Inc. — COM | 0.76% | 3,701,719 | Not disclosed | $150,400,843.00Jun 30, 2026 | Not disclosed |
| CUSIP 76029N106Replimune Group, Inc. — COM | 0.61% | 11,045,336 | Not disclosed | $122,271,870.00Jun 30, 2026 | Not disclosed |
| CUSIP 67080M103Nurix Therapeutics, Inc. — COM | 0.57% | 4,658,556 | Not disclosed | $113,016,569.00Jun 30, 2026 | Not disclosed |
| CUSIP 86150R107Stoke Therapeutics, Inc. — COM | 0.55% | 3,336,697 | Not disclosed | $109,176,726.00Jun 30, 2026 | Not disclosed |
| CUSIP 61225M102Monte Rosa Therapeutics, Inc. — COM | 0.53% | 4,345,736 | Not disclosed | $105,166,811.00Jun 30, 2026 | Not disclosed |
| CUSIP N44445109Immatics N.V. — SHS | 0.48% | 9,508,565 | Not disclosed | $96,321,763.00Jun 30, 2026 | Not disclosed |
| CUSIP 24823R105Denali Therapeutics Inc. — COM | 0.48% | 3,734,336 | Not disclosed | $96,047,122.00Jun 30, 2026 | Not disclosed |
| CUSIP 22663K107Crinetics Pharmaceuticals, Inc. — COM | 0.44% | 2,351,465 | Not disclosed | $87,991,820.00Jun 30, 2026 | Not disclosed |
| CUSIP 252828108Dianthus Therapeutics, Inc. — COM | 0.42% | 852,164 | Not disclosed | $83,068,947.00Jun 30, 2026 | Not disclosed |
| CUSIP 86366E106Structure Therapeutics Inc. — SPONSORED ADS | 0.39% | 1,432,529 | Not disclosed | $76,883,831.00Jun 30, 2026 | Not disclosed |
| CUSIP 75383L102Rapport Therapeutics, Inc. — COM | 0.32% | 1,547,090 | Not disclosed | $64,467,240.00Jun 30, 2026 | Not disclosed |
| CUSIP 022307102Alumis Inc. — COM | 0.28% | 2,012,500 | Not disclosed | $56,631,750.00Jun 30, 2026 | Not disclosed |
| CUSIP 74065P101Prelude Therapeutics Inc. — COM | 0.27% | 10,123,824 | Not disclosed | $53,959,982.00Jun 30, 2026 | Not disclosed |
| CUSIP 75943R102Relay Therapeutics, Inc. — COM | 0.27% | 2,826,783 | Not disclosed | $52,889,110.00Jun 30, 2026 | Not disclosed |
| CUSIP 604749101Mirum Pharmaceuticals, Inc. — COM | 0.26% | 445,975 | Not disclosed | $52,210,293.00Jun 30, 2026 | Not disclosed |
| CUSIP 088786108Bicycle Therapeutics plc — SPONSORED ADS | 0.23% | 10,885,357 | Not disclosed | $46,153,914.00Jun 30, 2026 | Not disclosed |
| CUSIP 29337E102Enliven Therapeutics, Inc. — COM | 0.23% | 905,191 | Not disclosed | $45,938,443.00Jun 30, 2026 | Not disclosed |
| CUSIP 15117B202Celldex Therapeutics, Inc. — COM | 0.22% | 1,182,611 | Not disclosed | $44,004,955.00Jun 30, 2026 | Not disclosed |
| CUSIP 92790C104Viridian Therapeutics, Inc. — COM | 0.22% | 2,383,025 | Not disclosed | $43,776,169.00Jun 30, 2026 | Not disclosed |
| CUSIP 25056L103Design Therapeutics, Inc. — COM | 0.19% | 2,678,430 | Not disclosed | $38,756,882.00Jun 30, 2026 | Not disclosed |
| CUSIP 29384C108Entrada Therapeutics, Inc. — COM | 0.19% | 5,072,730 | Not disclosed | $37,335,293.00Jun 30, 2026 | Not disclosed |
| CUSIP 81728A207Faeth Therapeutics, Inc. — COM | 0.16% | 1,286,411 | Not disclosed | $32,160,275.00Jun 30, 2026 | Not disclosed |
| CUSIP 01021M104Aktis Oncology, Inc. — COM | 0.16% | 996,351 | Not disclosed | $32,112,393.00Jun 30, 2026 | Not disclosed |
| CUSIP 64135M105Neurogene Inc. — COM | 0.16% | 991,691 | Not disclosed | $31,188,682.00Jun 30, 2026 | Not disclosed |
| CUSIP 008064206Jade Biosciences, Inc. — COM | 0.14% | 1,230,426 | Not disclosed | $27,340,066.00Jun 30, 2026 | Not disclosed |
| CUSIP 877619106Taysha Gene Therapies, Inc. — COM SHS | 0.14% | 4,004,756 | Not disclosed | $27,272,388.00Jun 30, 2026 | Not disclosed |
| CUSIP 03969F109Arcus Biosciences, Inc. — COM | 0.13% | 844,816 | Not disclosed | $26,045,677.00Jun 30, 2026 | Not disclosed |
| CUSIP 254604101Disc Medicine, Inc. — COM | 0.13% | 349,657 | Not disclosed | $25,573,913.00Jun 30, 2026 | Not disclosed |
| CUSIP 00091E109Absci Corporation — COM | 0.12% | 2,134,803 | Not disclosed | $24,742,367.00Jun 30, 2026 | Not disclosed |
| CUSIP 370920100Generate Biomedicines, Inc. — COM SHS | 0.12% | 1,423,602 | Not disclosed | $24,016,166.00Jun 30, 2026 | Not disclosed |
| CUSIP 23306J309DBV Technologies S.A. — SPONSORED ADS | 0.12% | 1,461,425 | Not disclosed | $23,967,370.00Jun 30, 2026 | Not disclosed |
| CUSIP 98420N105Xenon Pharmaceuticals Inc. — COM | 0.11% | 370,208 | Not disclosed | $22,345,755.00Jun 30, 2026 | Not disclosed |
| CUSIP 878972108Tectonic Therapeutic, Inc. — COM | 0.11% | 607,788 | Not disclosed | $20,892,713.00Jun 30, 2026 | Not disclosed |
| CUSIP 157085101Cerus Corporation — COM | 0.09% | 6,395,431 | Not disclosed | $18,674,659.00Jun 30, 2026 | Not disclosed |
| CUSIP 23284F105CytomX Therapeutics, Inc. — COM | 0.09% | 4,975,826 | Not disclosed | $18,659,348.00Jun 30, 2026 | Not disclosed |
| CUSIP 26818M108Dyne Therapeutics, Inc. — COM | 0.09% | 813,449 | Not disclosed | $18,066,702.00Jun 30, 2026 | Not disclosed |
| CUSIP 23282W605Cytokinetics, Incorporated — COM | 0.09% | 211,267 | Not disclosed | $17,997,836.00Jun 30, 2026 | Not disclosed |
| CUSIP 98401F105Xencor, Inc. — COM | 0.09% | 1,102,106 | Not disclosed | $17,743,907.00Jun 30, 2026 | Not disclosed |
| CUSIP 829401108Sionna Therapeutics, Inc. — COM | 0.09% | 400,000 | Not disclosed | $17,596,000.00Jun 30, 2026 | Not disclosed |
| CUSIP 45826J105Intellia Therapeutics, Inc. — COM | 0.08% | 930,232 | Not disclosed | $15,739,525.00Jun 30, 2026 | Not disclosed |
| CUSIP 698955101Parabilis Medicines, Inc. — COM | 0.07% | 500,000 | Not disclosed | $13,685,000.00Jun 30, 2026 | Not disclosed |
| CUSIP 56565P103MapLight Therapeutics, Inc. — COM | 0.07% | 364,705 | Not disclosed | $13,071,027.00Jun 30, 2026 | Not disclosed |
| CUSIP 05348Y105Avalyn Pharma Inc. — COM SHS | 0.06% | 350,000 | Not disclosed | $11,522,000.00Jun 30, 2026 | Not disclosed |
| CUSIP 30054Y107Evommune, Inc. — COM SHS | 0.06% | 847,390 | Not disclosed | $11,261,813.00Jun 30, 2026 | Not disclosed |
| CUSIP 09075V102BioNTech SE — SPONSORED ADS | 0.06% | 119,743 | Not disclosed | $11,142,086.00Jun 30, 2026 | Not disclosed |
| CUSIP 87583X109Tango Therapeutics, Inc. — COM | 0.05% | 333,333 | Not disclosed | $10,419,990.00Jun 30, 2026 | Not disclosed |
| CUSIP 05338F306Avalo Therapeutics, Inc. — COM | 0.05% | 550,000 | Not disclosed | $10,164,000.00Jun 30, 2026 | Not disclosed |
| CUSIP 81749D107Sera Prognostics, Inc. — CLASS A COM | 0.05% | 5,498,170 | Not disclosed | $10,006,669.00Jun 30, 2026 | Not disclosed |
| CUSIP 92337C203Verastem, Inc. — COM | 0.05% | 2,499,338 | Not disclosed | $9,547,471.00Jun 30, 2026 | Not disclosed |
| CUSIP 786700104Sagimet Biosciences Inc. — COM SER A | 0.04% | 952,996 | Not disclosed | $7,366,659.00Jun 30, 2026 | Not disclosed |
| CUSIP 282564103Eikon Therapeutics, Inc. — COM | 0.04% | 555,555 | Not disclosed | $7,249,993.00Jun 30, 2026 | Not disclosed |
| CUSIP 50180M108LB Pharmaceuticals Inc. — COM SHS | 0.03% | 200,000 | Not disclosed | $6,491,000.00Jun 30, 2026 | Not disclosed |
| CUSIP 918385204vTv Therapeutics, Inc. — CL A | 0.03% | 148,314 | Not disclosed | $5,584,022.00Jun 30, 2026 | Not disclosed |
| CUSIP Y95308105Wave Life Sciences Ltd. — SHS | 0.02% | 822,638 | Not disclosed | $4,779,527.00Jun 30, 2026 | Not disclosed |
| CUSIP 74365U107Protara Therapeutics, Inc. — COM STK | 0.02% | 971,614 | Not disclosed | $3,711,565.00Jun 30, 2026 | Not disclosed |
| CUSIP 89854M101TScan Therapeutics, Inc. — COM | 0.01% | 2,784,792 | Not disclosed | $2,729,375.00Jun 30, 2026 | Not disclosed |
| CUSIP 45257U108Immunome, Inc. — COM | 0.01% | 55,306 | Not disclosed | $1,171,934.00Jun 30, 2026 | Not disclosed |
| CUSIP 83086J200Skye Bioscience, Inc. — COM | 0.01% | 1,575,243 | Not disclosed | $1,092,116.00Jun 30, 2026 | Not disclosed |
| CUSIP 799566104Sana Biotechnology, Inc. — COM | 0.01% | 310,483 | Not disclosed | $1,083,586.00Jun 30, 2026 | Not disclosed |
| CUSIP 01626L204Aligos Therapeutics, Inc. — COM | 0% | 83,055 | Not disclosed | $479,227.00Jun 30, 2026 | Not disclosed |
| CUSIP 90240B106Tyra Biosciences, Inc. — COM | 0% | 10,607 | Not disclosed | $338,788.00Jun 30, 2026 | Not disclosed |
| CUSIP 86889P117Surrozen, Inc. Warrants @ $172.50 8/11/2026 (15 FOR 1) — W EXP 8/11/2026 | 0% | 833,333 | Not disclosed | $13,750.00Jun 30, 2026 | Not disclosed |
Only part of the portfolio is public
Stock P&L requires a disclosed position cost basis and a dated valuation in the same currency. It is unrealized price P&L and excludes dividends and realized gains. Missing inputs stay undisclosed.
